

Review Article



Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives

Srinivasa B^{1*}, Devika P Jeeragyal², Kiran Velukuri³, Amarnath Reganti⁴, Vaheedha S⁵, Vinodhkumar Ramalingam⁵, Rajasekar Sreerama⁶, Neelima Grandhe⁶, Praveen Hoogar⁷

¹Department of Pharmacology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai Tamil Nadu, India

²Department of Community Medicine, Apollo Institute of Medical Sciences And Research Chittoor, India

³Department of Physiotherapy, Apollo College of Physiotherapy, the Apollo Knowledge Centre, Murukambattu, Chittoor 517127, India

⁴Division of Allied Health Sciences, School of Health Sciences, the Apollo University, Murukambattu, Chittoor, India

⁵Saveetha College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai, India

⁶Department of Pharmaceutical Chemistry, Apollo Institute of Pharmaceutical Sciences, The Apollo University, The Apollo Knowledge City Saketa, Chittoor, India

⁷School of Social Sciences, The Apollo University, Chittoor, India

Article info

Article History:

Received: February 14, 2026

Revised: April 1, 2026

Accepted: May 7, 2026

published: May 23, 2026

Keywords:

Cell cycle, Colorectal neoplasms, Cyclin-dependent kinases, DNA methylation, Epigenesis, Histone modification

Abstract

Introduction: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance.

Methods: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies.

Results: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin-CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies.

Conclusion: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.

Introduction

Global Burden of Colorectal Cancer

Colorectal cancer (CRC) constitutes a significant global health burden and continues to rank among the leading malignancies in both incidence and mortality, with recent GLOBOCAN estimates reporting nearly 1.9 million new cases and over 900,000 deaths annually.^{1,2} Although historically more prevalent in high-income regions, the incidence of CRC is increasingly rising in low- and middle-income countries, largely driven by transitions in lifestyle patterns including dietary habits, reduced physical activity,

obesity and demographic aging.³⁻⁶ Notwithstanding improvements in screening and therapeutic modalities, CRC remains associated with considerable morbidity and mortality particularly in advanced disease stages.^{7,8} Additionally, the growing incidence of early-onset CRC highlights the contribution of distinct biological and environmental influences in younger populations.⁹⁻¹¹ At the molecular level, colorectal carcinogenesis is driven by complex interactions between genetic alterations and epigenetic dysregulation that collectively disrupt cellular homeostasis. Aberrant control of key regulatory pathways,

*Corresponding Author: Srinivasa B, Email: srinivasab.smc@saveetha.com

© 2026 The Author (s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

particularly those governing cell cycle progression and checkpoint integrity, plays a central role in tumor initiation and progression. Collectively, these trends emphasize the necessity of elucidating the underlying molecular mechanisms of colorectal tumorigenesis, with particular focus on pathways governing cell cycle regulation and epigenetic modifications which may provide critical insights for the development of targeted and mechanism-based therapeutic strategies.¹²

Literature Identification and Critical Analytical Approach

This article is presented as a mechanistic critical review synthesizing published evidence on epigenetic regulation of cell cycle control in colorectal cancer. Relevant experimental, translational and clinical studies were identified through targeted literature exploration and evaluated using a conceptual and analytical framework. A structured literature search was conducted using electronic databases including PubMed, Scopus and Web of Science. Key search terms included “colorectal cancer”, “epigenetics”, “DNA methylation”, “histone modification”, “non-coding RNA”, “cell cycle regulation” and “cyclin-dependent kinases”. Studies published in English focusing on molecular mechanisms, translational relevance and therapeutic implications were considered. Priority was given to recent high-impact studies and seminal reports in the field. This review does not follow PRISMA guidelines, does not employ formal risk-of-bias assessment, and is not intended as a systematic review or meta-analysis.

Importance of Cell Cycle Dysregulation in Colorectal Cancer

Sustained and uncontrolled cellular proliferation is a defining hallmark of cancer and dysregulation of the cell cycle plays a central role in colorectal tumor initiation and progression.¹³ Under normal physiological conditions, cell cycle progression is governed by a tightly coordinated

network of cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors that regulate orderly transitions through the G1, S, G2 and M phases, thereby preserving genomic integrity and ensuring controlled cell division.^{14,15} Critical surveillance checkpoints, particularly at the G1/S and G2/M transitions, function to prevent replication and propagation of damaged DNA.¹⁶

In colorectal cancer, this finely tuned regulatory system is frequently disrupted. Aberrant overexpression of cyclins such as cyclin D1, constitutive activation of CDKs and functional loss or epigenetic silencing of CDK inhibitors including p16^{INK4a}, p21^{Cip1} and p27^{Kip1} collectively drive unchecked cell cycle progression.^{17,18} These alterations promote uncontrolled proliferation, chromosomal instability and progressive accumulation of oncogenic mutations, thereby accelerating tumor growth and disease progression.¹⁹ (Figure 1)

Genomic instability arising from defective checkpoint control further fuels tumor evolution and intratumoral heterogeneity. Moreover, impaired cell cycle regulation contributes to resistance against cytotoxic chemotherapy and radiotherapy, as defective checkpoints allow cancer cells to evade apoptosis and survive genotoxic stress.^{20,21} Consequently, delineating the upstream regulatory mechanisms governing cell cycle dysregulation has become essential for identifying novel therapeutic targets in colorectal cancer.²² (Table 1)

Emergence of Epigenetics as a Regulatory Layer

Beyond irreversible genetic mutations, epigenetic alterations have emerged as a pivotal regulatory layer that shapes gene expression and cellular behavior in colorectal cancer.²³ Epigenetics refers to heritable yet reversible modifications that influence chromatin architecture and gene expression without altering the DNA sequence, predominantly mediated through DNA methylation, histone modifications, and regulatory non-coding RNAs.^{24–26} These mechanisms are essential for normal




Figure 1. Epigenetic regulation of cell cycle checkpoints in colorectal cancer. Epigenetic alterations, including promoter hypermethylation and aberrant histone modifications, suppress transcription of cyclin-dependent kinase inhibitors such as p16^{INK4a}, p21^{Cip1} and p27^{Kip1}. This repression results in sustained activation of cyclin-CDK complexes, bypass of the G1/S checkpoint and uncontrolled cellular proliferation characteristic of colorectal tumorigenesis

Table 1. Summary of key epigenetic alterations influencing cell cycle checkpoint disruption during colorectal cancer progression

CRC stage / context	Key epigenetic alteration	Primary target(s)	Checkpoint / pathway impact	Functional outcome
Early adenoma formation	Promoter hypermethylation	CDKN2A (p16 ^{INK4a})	G1/S checkpoint bypass	Enhanced proliferation and clonal expansion (e.g., CDKN2A/p16 ^{INK4a} silencing, SFRP1-mediated Wnt activation)
Progressive dysplasia	Histone deacetylation	CDKN1A (p21 ^{Cip1})	Reduced CDK inhibition	Increased cell cycle progression and checkpoint evasion (e.g., CDKN1A/p21 ^{Cip1} repression, GADD45A downregulation)
Advanced tumor growth	Chromatin remodeling dysregulation	CDKN1B (p27 ^{Kip1})	Cyclin-CDK activation	Loss of growth control and sustained proliferation (e.g., CDKN1B/p27 ^{Kip1} downregulation, CCNE1 overexpression)
Metastatic progression	Global hypomethylation	Genome-wide instability loci	Chromosomal instability	Increased invasiveness and phenotypic plasticity (e.g., CDH1 silencing promoting EMT, CXCR4 activation)
Therapy-resistant subclones	Epigenetic plasticity	Multiple tumor suppressor pathways	Checkpoint adaptation	Resistance to chemo/radiotherapy and survival advantage (e.g., ABCB1 upregulation, BCL2L1-mediated apoptosis resistance)

development and tissue homeostasis and their disruption is increasingly regarded as a fundamental contributor to malignant transformation.²⁷

Colorectal cancer exhibits extensive epigenetic reprogramming, characterized by global DNA hypomethylation, promoter-specific hypermethylation of tumor suppressor genes, abnormal histone acetylation and methylation signatures and dysregulated microRNA expression.²⁸⁻³⁰ Such epigenetic remodeling not only alters transcriptional output but also provides colorectal tumor cells with adaptive plasticity that supports proliferation, survival, and therapeutic resistance. Large-scale epigenomic and transcriptomic profiling studies, including those conducted by The Cancer Genome Atlas, have identified distinct molecular and epigenetic subtypes of colorectal cancer with characteristic DNA methylation and chromatin modification signatures that correlate with tumor behavior, disease progression and therapeutic response.^{30,31}

Epigenetic mechanisms directly modulate the transcription of key cell cycle regulators, thereby linking environmental exposures and oncogenic signaling pathways to cell cycle control.³²⁻³⁴ Importantly, epigenetic alterations often occur early during colorectal tumorigenesis and may precede irreversible genetic mutations, suggesting a critical role in disease initiation.^{35,36} In contrast to fixed genetic lesions, epigenetic dysregulation is inherently dynamic and may be pharmacologically reprogrammed, positioning it as a promising target for therapeutic intervention. Increasing evidence indicates that pharmacological modulation of epigenetic regulators, such as DNA methyltransferases and histone deacetylases, can restore cell cycle checkpoint function and enhance sensitivity to conventional anticancer therapies.³⁷⁻³⁹ Collectively, these observations highlight epigenetic regulation of cell cycle control as a promising and rational therapeutic avenue in colorectal cancer management.⁴⁰⁻⁴⁹

The overall conceptual framework and organization of this review are aligned with contemporary review articles in the field, emphasizing mechanistic insight and translational relevance in biomedical research.⁵⁰

Cell Cycle Regulation in Colorectal Cancer

a) Overview of the Cell Cycle Machinery

The eukaryotic cell cycle represents a highly ordered regulatory program designed to coordinate genome duplication with accurate chromosomal partitioning during cell division. Progression through this program is conventionally organized into four phases G1, S, G2 and M and is driven by cyclical fluctuations in cyclin-dependent kinase (CDK) activity.^{51,52} CDKs exert their function through association with phase-specific cyclins, generating enzymatic complexes whose activation is precisely timed to enforce directional movement through the cell cycle.⁵³

Distinct cyclin-CDK assemblies orchestrate key transition points. Cyclin D-CDK4/6 complexes initiate early G1 progression, whereas cyclin E-CDK2 serves as a critical regulator of the G1/S checkpoint. DNA replication during S phase is primarily supported by cyclin A-CDK2, while cyclin B-CDK1 activity triggers mitotic entry.^{54,55} Because CDKs act as central gatekeepers of replication and division, stringent regulation of their activation is essential. Dysregulated CDK signaling can induce replication stress, promote DNA damage accumulation and accelerate chromosomal instability.⁵⁶

Multiple regulatory mechanisms restrain CDK activity, including inhibitory phosphorylation, ubiquitin-mediated degradation of cyclins, and inhibition by cyclin-dependent kinase inhibitors (CDKIs).⁵⁷ These safeguards collectively ensure that cell cycle progression occurs only under conditions favorable for genomic integrity.

b) Cell Cycle Checkpoints and Their Disruption in Colorectal Cancer

Cell cycle checkpoints act as regulatory surveillance barriers that assess genomic integrity and cellular preparedness before allowing progression through the cell cycle. The G1/S checkpoint restricts entry into S phase to prevent duplication of damaged DNA, whereas the G2/M checkpoint verifies that DNA replication is complete and that repair processes have been adequately executed before mitotic entry.⁵⁸ These checkpoints are governed by tumor suppressor pathways, most notably the p53-p21 axis and

the retinoblastoma (RB) pathway.⁵⁹

In colorectal cancer, checkpoint integrity is frequently compromised through genetic and epigenetic alterations. Functional inactivation of p53, deregulation of RB signaling, and aberrant activation of CDKs collectively enable cancer cells to bypass checkpoint control.^{60,61} This permissive environment allows proliferation despite genomic damage, accelerating mutation accumulation and tumor evolution.⁶² Sustained checkpoint failure also contributes to chromosomal instability, a defining molecular feature of colorectal cancer associated with aggressive disease and poor prognosis.⁶³

Checkpoint dysfunction has important therapeutic implications. Colorectal cancer cells with defective checkpoints often rely on residual DNA damage response pathways for survival, rendering them selectively vulnerable to therapies targeting replication stress and mitotic control.^{64,65}

Epigenetic Mechanisms in Colorectal Cancer

a) DNA Methylation and Transcriptional Control

DNA methylation refers to the enzymatic transfer of a methyl group onto cytosine bases, predominantly within CpG dinucleotides, a reaction mediated by DNA methyltransferases. This modification is essential for physiological gene regulation, maintaining chromosomal integrity, and ensuring stable epigenomic patterning during development.⁶⁶ In colorectal cancer, methylation landscapes are frequently distorted, displaying widespread genomic hypomethylation alongside focal CpG island hypermethylation at promoter regions of tumor suppressor genes.^{67,68} Functionally, promoter-directed hypermethylation creates a transcriptionally repressive environment that restricts expression of genes governing checkpoint enforcement, programmed cell death, and DNA damage repair. In colorectal carcinogenesis, such silencing events often arise early and may act as initiating molecular switches that predispose cells to unchecked proliferation and progressive malignant transformation.⁶⁹ A well-recognized manifestation of this phenomenon is the CpG island methylator phenotype, which defines a distinct CRC subtype marked by extensive promoter hypermethylation and characteristic clinicopathological associations.^{70,71}

b) Histone Modifications and Chromatin Remodeling

Histones serve as dynamic regulatory scaffolds, and their post-translational modification including acetylation, methylation, phosphorylation and ubiquitination shapes chromatin architecture and transcriptional permissiveness.⁷² Among these modifications, histone acetylation typically promotes chromatin relaxation and facilitates transcription, whereas histone deacetylation promotes a compact chromatin state and transcriptional repression. These processes are regulated through the opposing actions of histone acetyltransferases and histone deacetylases. In colorectal cancer, aberrant deacetylase activity has been linked to inappropriate chromatin compaction and repression of tumor suppressor pathways, including those required for cell cycle arrest.^{73,74} Histone methylation introduces an additional regulatory dimension, as its transcriptional impact depends on both the specific residue modified and the extent of methyl group deposition. Dysregulated expression or catalytic activity of histone methyltransferases and demethylases has been implicated in colorectal tumorigenesis through epigenomic reprogramming of genes controlling proliferation, checkpoint signaling, and cellular fate decisions.^{75,76} (Figure 2)

c) Role of Non-Coding RNAs

Non-coding RNAs constitute a critical epigenetic regulatory axis capable of modulating gene expression at both transcriptional and post-transcriptional levels (Table 2). MicroRNAs can suppress cell cycle progression by directly targeting mRNAs encoding cyclins, cyclin-dependent kinases and checkpoint inhibitory proteins, thereby reshaping proliferative signaling in colorectal cancer cells.^{77,78} In parallel, long non-coding RNAs contribute to epigenetic remodeling by functioning as molecular scaffolds or guides that recruit chromatin-modifying complexes to defined genomic loci, enabling locus-specific transcriptional activation or repression.^{79,80}

Despite substantial evidence implicating DNA methylation, histone modifications and chromatin remodeling in colorectal cancer progression, the relative contribution of individual epigenetic mechanisms remains context dependent. Studies differ in the extent to which specific epigenetic alterations function as primary drivers versus secondary adaptations to oncogenic signaling,

Table 2. Representative non-coding RNAs modulating epigenetic regulators and cell cycle signaling in colorectal cancer

Non-coding RNA type	Representative molecule	Epigenetic mechanism	Cell cycle target	Functional implication in CRC
microRNA	miR-34a	p53-regulated miRNA that suppresses CDK6 and cyclin D1, enforcing cell cycle arrest	CDK6, cyclin D1	G1 arrest and tumor suppression
microRNA	miR-21	Targets tumor suppressors such as PTEN and PDCD4, leading to enhanced proliferation and reduced apoptosis	PTEN, p21 axis	Enhanced proliferation and survival
lncRNA	HOTAIR	Recruits PRC2 complex to mediate H3K27 trimethylation and gene silencing	p21/p27-associated pathways	Promotion of invasion and proliferation
lncRNA	MALAT1	Regulates alternative splicing and transcriptional control of cell cycle genes	Cell cycle regulators	Enhanced proliferation and metastatic potential
circRNA	circHIPK3	Acts as a ceRNA by sponging miR-124 and miR-7, promoting proliferation-associated gene expression.	CDK inhibitors	Cell cycle progression and growth advantage




Figure 2. Molecular epigenetic mechanisms governing cyclin-dependent kinase inhibitor expression in colorectal cancer. DNA methylation and histone deacetylation cooperate to induce chromatin condensation and transcriptional repression of CDK inhibitor genes, whereas epigenetic reprogramming can restore chromatin accessibility and checkpoint integrity

and in some cases, opposing epigenetic states have been reported across molecular subtypes. This variability likely reflects tumor heterogeneity, differences in experimental models, and dynamic temporal regulation during disease evolution. Consequently, epigenetic mechanisms should not be viewed as uniform oncogenic switches but rather as flexible regulatory processes whose functional impact depends on cellular context and disease stage.

Epigenetic Regulation of Cell Cycle Control

Epigenetic regulation is pivotal in orchestrating cell cycle progression by controlling chromatin structure and transcriptional access to key regulators such as cyclins, cyclin-dependent kinases (CDKs), and their endogenous inhibitors. In colorectal cancer, these epigenetic modifications act as dynamic molecular switches that integrate environmental influences, oncogenic pathways, and cellular stress signals, ultimately reprogramming cell cycle checkpoints.^{81,82} Unlike genetic mutations, epigenetic alterations occur without changing the underlying DNA sequence, but exert profound effects on transcriptional output, thereby enabling cancer cells to sustain proliferative signaling while retaining phenotypic plasticity.⁸³

Aberrant DNA methylation, histone modification patterns and non-coding RNA networks converge to suppress cell cycle checkpoint regulators and enhance cyclin-CDK activity. This coordinated epigenetic reprogramming permits colorectal cancer cells to bypass growth-inhibitory signals, evade senescence and tolerate genomic instability.^{84,85} Importantly, epigenetic control of cell cycle is context dependent and reversible, positioning it as a critical interface between tumor biology and therapeutic intervention.

Epigenetic Control of CDK Inhibitors

Cyclin-dependent kinase inhibitors (CDKIs) serve as key molecular brakes that restrain CDK activity and preserve checkpoint fidelity. Among these, p16^{INK4a}, p21^{Cip1} and p27^{Kip1} are central regulators of G1/S phase transition and are frequent targets of epigenetic silencing in colorectal cancer.⁸⁶

p16^{INK4a} selectively inhibits CDK4 and CDK6, preventing phosphorylation of the retinoblastoma protein and enforcing G1-phase arrest. In colorectal cancer, promoter hypermethylation of the *CDKN2A* locus is a common epigenetic event that leads to transcriptional silencing of p16^{INK4a}.⁸⁷ Loss of p16^{INK4a} expression results in sustained cyclin D-CDK4/6 activity, enabling unchecked cell cycle entry despite growth-inhibitory cues.

p21^{Cip1}, a downstream effector of p53 signaling, functions as a broad-spectrum CDK inhibitor linking DNA damage responses to cell cycle arrest. Epigenetic repression of *CDKN1A* through histone deacetylation or altered chromatin occupancy disrupts p21^{Cip1} mediated checkpoint control, thereby decoupling DNA damage sensing from proliferative restraint.⁸⁸ This dysregulation contributes to resistance against genotoxic therapies and facilitates survival under replicative stress.

p27^{Kip1} primarily inhibits cyclin E-CDK2 and cyclin A-CDK2 complexes, regulating late G1 and S-phase progression. Reduced expression of p27^{Kip1} in colorectal cancer is frequently driven by epigenetic mechanisms, including microRNA mediated repression and chromatin remodeling, rather than direct genetic alterations.⁸⁹ Loss of p27^{Kip1} promotes sustained CDK2 activity and correlates with aggressive tumor behavior and poor clinical outcomes.

Collectively, epigenetic suppression of CDK inhibitors dismantles checkpoint control and establishes a permissive proliferative state, highlighting these molecules as critical nodes linking chromatin dynamics to cell cycle deregulation in colorectal cancer.⁹⁰

While epigenetic silencing of cyclin-dependent kinase inhibitors represents a consistent mechanistic feature of colorectal cancer, translation of these insights into clinical practice remains limited. Reduced expression of p16^{INK4a}, p21^{Cip1} and p27^{Kip1} has been variably associated with aggressive tumor behavior, therapeutic resistance and adverse outcomes; however, these relationships are not uniformly predictive across patient cohorts. This inconsistency underscores the influence of epigenetic context and co-existing molecular alterations. Integrating CDK inhibitor status with broader epigenetic and transcriptomic profiles may therefore be necessary to realize their full prognostic and therapeutic potential.

Therapeutic Implications of Targeting Epigenetic Regulators

The reversible nature of epigenetic modifications provides a compelling biological rationale for therapeutic intervention in colorectal cancer. Unlike permanent genetic alterations, epigenetic changes can be pharmacologically modulated, enabling restoration of transcriptional programs governing cell cycle arrest, apoptosis, and cellular differentiation.^{91,92} Consequently, epigenetic therapies offer the potential to re-establish tumor suppressor function rather than merely suppress downstream oncogenic signaling pathways. DNA methyltransferase inhibitors represent one of the most extensively investigated classes of epigenetic agents. Aberrant promoter hypermethylation is a frequent

mechanism underlying transcriptional silencing of cyclin-dependent kinase inhibitors in colorectal cancer.⁹³ Pharmacological inhibition of DNMTs can reverse this silencing, leading to re-expression of genes such as CDKN2A and restoration of G1/S checkpoint control.⁹⁴ Preclinical studies consistently demonstrate that demethylating agents suppress proliferation, induce cell cycle arrest, and enhance apoptotic sensitivity in colorectal cancer models.⁹⁵

Histone deacetylase inhibitors constitute another major class of epigenetic therapeutics with direct relevance to cell cycle regulation. By promoting histone acetylation and chromatin relaxation, HDAC inhibitors facilitate transcriptional activation of growth-inhibitory genes, including p21^{Cip1} and p27^{Kip1}.⁹⁶ This reactivation attenuates CDK activity and reinforces cell cycle checkpoint control. Beyond cytostatic effects, HDAC inhibitors modulate multiple oncogenic pathways, including DNA damage response signaling and apoptotic machinery.⁹⁷ Importantly, accumulating evidence suggests that epigenetic therapies may exert their greatest clinical benefit when employed as part of combination strategies rather than as monotherapies (Figure 3).

Epigenetic priming has been shown to sensitize colorectal cancer cells to chemotherapy, radiotherapy, and targeted agents by restoring apoptotic competence and checkpoint integrity.⁹⁸ Combination regimens integrating epigenetic modulators with CDK4/6 inhibitors or immune checkpoint inhibitors are therefore emerging as promising approaches to overcome therapeutic resistance.^{99,100}

Despite encouraging preclinical findings, clinical translation of epigenetic therapies in colorectal cancer remains challenging. Limited target specificity, dose-limiting toxicities, and marked interpatient heterogeneity




Figure 3. Therapeutic targeting of the epigenetic-cell cycle axis in colorectal cancer. Pharmacological inhibition of DNA methyltransferases and histone deacetylases restores tumor suppressor gene expression, reinforces cell cycle checkpoints, and enhances sensitivity to conventional anticancer therapies

have constrained their widespread adoption.¹⁰¹ These limitations underscore the need for robust predictive biomarkers to guide patient selection and optimize rational therapeutic combinations

Challenges, Knowledge Gaps, and Future Directions

Although significant advances have been achieved in understanding how epigenetic mechanisms regulate cell cycle progression, several key challenges still persist (Table 3). One major limitation is the context-dependent nature of epigenetic alterations. The functional consequences of DNA methylation or histone modification are influenced by tumor subtype, cellular differentiation state and micro-environmental cues, complicating therapeutic targeting.¹⁰²

Another unresolved issue is the lack of specificity of current epigenetic drugs. Global modulation of DNA methylation or histone acetylation may inadvertently affect normal cells, leading to off-target effects and toxicity.¹⁰³ The development of next-generation epigenetic therapies with locus-specific or enzyme-selective activity is therefore a critical unmet need.¹⁰⁴

Tumor heterogeneity further complicates therapeutic intervention. Epigenetic landscapes vary not only between patients but also within individual tumors, enabling adaptive resistance and disease progression.¹⁰⁵ Single cell epigenomic technologies have begun to reveal this heterogeneity, but integration of these insights into clinical decision-making remains in its infancy.¹⁰⁶

Future research should focus on defining epigenetic signatures that predict response to therapy, identifying combinatorial vulnerabilities linking epigenetic dysregulation to cell cycle dependence, and developing precision epigenetic editing approaches.¹⁰⁷ Recent developments in CRISPR-based epigenome editing and integrated multi-omics approaches provide powerful new avenues to unravel causal links between chromatin dynamics and cell cycle regulation (Figure 4).¹⁰⁸

Ultimately, translating epigenetic insights into durable clinical benefit will require a shift toward mechanism-driven, biomarker-guided therapeutic strategies that account for tumor heterogeneity and dynamic epigenetic plasticity.¹⁰⁹ Such approaches hold promise for improving outcomes in colorectal cancer by exploiting the reversible nature of epigenetic regulation.¹¹⁰

Conclusion

Colorectal cancer illustrates how malignant progression can arise not only from fixed genetic lesions but also from dynamic and reversible disruptions in regulatory architecture. The evidence synthesized in this review positions epigenetic control of the cell cycle as a central organizing principle in colorectal tumor biology, rather than a secondary or accessory process. Through coordinated modulation of chromatin accessibility and transcriptional output, epigenetic alterations recalibrate proliferative thresholds, enabling colorectal cancer cells to bypass checkpoint constraints while maintaining adaptability to environmental and therapeutic pressures.

A defining feature of this regulatory rewiring is the epigenetic attenuation of cyclin-dependent kinase inhibitors such as p16^{INK4a}, p21^{Cip1} and p27^{Kip1}. Loss of these molecular brakes does not simply accelerate cell division; it fundamentally alters how colorectal cancer cells interpret DNA damage, metabolic stress, and growth-inhibitory cues. In this context, the cell cycle shifts from a regulated decision-making framework to a permissive, self-reinforcing driver of tumor evolution. Importantly, such changes often precede irreversible genetic instability, suggesting that epigenetic dysregulation functions as an early architect of malignant behavior.

From a therapeutic standpoint, epigenetic regulation of the cell cycle represents an opportunity to intervene upstream of established oncogenic dependency. Rather than targeting isolated signaling nodes, epigenetic strategies offer the potential to restore regulatory balance across entire checkpoint networks. Realizing this potential, however, will require moving beyond global chromatin modulation toward precision approaches that account for tumor subtype, epigenetic context, and intratumoral heterogeneity.

Looking forward, the convergence of epigenomics, cell cycle biology, and systems-level analytics provides a pathway toward redefining therapeutic vulnerability in colorectal cancer. By conceptualizing the epigenome as an adaptive regulator of proliferative competence rather than a static layer of modification, future research may shift clinical paradigms from suppressing tumor growth to reinstating lost regulatory control, enabling more durable and context-aware strategies for colorectal cancer management.

Acknowledgements

The author gratefully acknowledges the academic environment and

Table 3. Key barriers limiting clinical translation of epigenetic therapies and strategies to improve colorectal cancer treatment outcomes

Challenge domain	Underlying epigenetic factor	Clinical consequence	Therapeutic implication	Future direction
Interpatient heterogeneity	Subtype-specific methylation signatures	Variable response to epigenetic drugs	Need biomarker-guided selection	Integrate methylome profiling into stratification
Intratumoral heterogeneity	Subclonal chromatin state diversity	Emergence of resistant subpopulations	Combination therapy requirement	Single-cell epigenomics-guided targeting
Off-target toxicity	Global chromatin modulation	Dose-limiting adverse effects	Restricted therapeutic window	Develop selective epigenetic inhibitors
Epigenetic plasticity	Dynamic reversible switching	Transient drug sensitivity	Adaptive resistance	Sequential/priming-based regimens
Lack of predictive biomarkers	Complex multi-layer regulation	Uncertain patient benefit	Trial failures	Multi-omic biomarker panels




Figure 4. Integrative model illustrating the interplay between epigenetic dysregulation, cell cycle control, and therapeutic response in colorectal cancer. Epigenetic alterations function as upstream regulators of proliferative competence and therapeutic sensitivity

institutional facilities that enabled access to scientific databases and literature essential for the completion of this review.

Authors' Contribution

Conceptualization: Srinivasa B, Devika P Jeeragyal
 Data curation: Kiran Velukuri, Neelima Grandhe, Vaheedha S, Dr Srinivasa B
 Formal analysis: Dr Srinivasa B, Amarnath Reganti, Praveen Hoogar
 Investigation: Devika P Jeeragyal, Vaheedha S, Vinodhkumar Ramalingam
 Methodology: Srinivasa B, Rajasekar Sreerama
 Project administration: Srinivasa B
 Resources: Vinodhkumar Ramalingam
 Software: Kiran Velukuri
 Supervision: Srinivasa B
 Validation: Dr Srinivasa B, Rajasekar Sreerama, Amarnath Reganti
 Writing—original draft: Devika P Jeeragyal, Neelima Grandhe
 Writing—review & editing: Srinivasa B, Kiran Velukuri, Praveen Hoogar, Rajasekar Sreerama

Competing Interests

The authors confirm that there are no financial or non-financial conflicts of interest related to this manuscript.

Ethical Approval

This manuscript is a literature-based review, includes no human / animal research and no identifiable personal data; therefore, ethical approval was not applicable.

Funding

This work was conducted without external financial support from public, commercial or not-for-profit funding agencies.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram

I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71(3):209-49. doi:10.3322/caac.21660

2. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. *Int J Cancer* 2021. doi:10.1002/ijc.33588
3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017;66(4):683-91. doi:10.1136/gutjnl-2015-310912
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68(6):394-424. doi:10.3322/caac.21492
5. Willett WC. Diet and cancer: one view at the start of the millennium. *Cancer Epidemiol Biomarkers Prev* 2001;10(1):3-8.
6. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. *CA Cancer J Clin* 2018;68(1):31-54. doi:10.3322/caac.21440
7. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet* 2019;394(10207):1467-80. doi:10.1016/s0140-6736(19)32319-0
8. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016;27(8):1386-422. doi:10.1093/annonc/mdw235
9. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. *J Natl Cancer Inst* 2017;109(8):djjw322.

- doi:10.1093/jnci/djw322
10. Patel SG, Ahnen DJ. Colorectal cancer in the young. *Curr Gastroenterol Rep* 2018;20(4):15. doi:10.1007/s11894-018-0618-9
 11. Fearon ER. Molecular genetics of colorectal cancer. *Annu Rev Pathol* 2011;6:479-507. doi:10.1146/annurev-pathol-011110-130235
 12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. *Science* 2013;339(6127):1546-58. doi:10.1126/science.1235122
 13. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov* 2022;12(1):31-46. doi:10.1158/2159-8290.Cd-21-1059
 14. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* 2009;9(3):153-66. doi:10.1038/nrc2602
 15. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. *Annu Rev Cell Dev Biol* 1997;13:261-91. doi:10.1146/annurev.cellbio.13.1.261
 16. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. *Nature* 2004;432(7015):316-23. doi:10.1038/nature03097
 17. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* 1999;13(12):1501-12. doi:10.1101/gad.13.12.1501
 18. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. *Nat Rev Cancer* 2008;8(9):714-24. doi:10.1038/nrc2401
 19. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. *Nat Rev Mol Cell Biol* 2010;11(3):220-8. doi:10.1038/nrm2858
 20. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer* 2017;17(2):93-115. doi:10.1038/nrc.2016.138
 21. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nat Rev Cancer* 2012;12(9):587-98. doi:10.1038/nrc3342
 22. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. *Nat Rev Drug Discov* 2015;14(2):130-46. doi:10.1038/nrd4504
 23. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. *Nat Rev Cancer* 2011;11(10):726-34. doi:10.1038/nrc3130
 24. Baylin SB, Jones PA. Epigenetic determinants of cancer. *Cold Spring Harb Perspect Biol* 2016;8(9):a019505. doi:10.1101/cshperspect.a019505
 25. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. *Nat Rev Genet* 2016;17(8):487-500. doi:10.1038/nrg.2016.59
 26. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. *Nature* 2007;447(7143):433-40. doi:10.1038/nature05919
 27. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. *Cell* 2012;150(1):12-27. doi:10.1016/j.cell.2012.06.013
 28. Issa JP. CpG island methylator phenotype in cancer. *Nat Rev Cancer* 2004;4(12):988-93. doi:10.1038/nrc1507
 29. Esteller M. Epigenetics in cancer. *N Engl J Med* 2008;358(11):1148-59. doi:10.1056/NEJMra072067
 30. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012;487(7407):330-7. doi:10.1038/nature11252
 31. Vasudevan K, Dhanushkumar T, Hebbar SR, Selvam PK, Rambabu M, Anbarasu K, et al. Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer. *Sci Rep* 2025;15(1):19333. doi:10.1038/s41598-025-01680-1
 32. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. *Semin Oncol* 2005;32(5):521-30. doi:10.1053/j.seminoncol.2005.07.003
 33. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128(4):683-92. doi:10.1016/j.cell.2007.01.029
 34. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 2003;349(21):2042-54. doi:10.1056/NEJMra023075
 35. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. *Curr Opin Genet Dev* 2012;22(1):50-5. doi:10.1016/j.gde.2012.02.008
 36. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. *Br J Cancer* 2008;98(6):1147-56. doi:10.1038/sj.bjc.6604259
 37. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A* 1999;96(15):8681-6. doi:10.1073/pnas.96.15.8681
 38. Lao VV, Grady WM. Epigenetics and colorectal cancer. *Nat Rev Gastroenterol Hepatol* 2011;8(12):686-700. doi:10.1038/nrgastro.2011.173
 39. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. *Nat Med* 2011;17(3):330-9. doi:10.1038/nm.2305
 40. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. *Carcinogenesis* 2010;31(1):27-36. doi:10.1093/carcin/bgp220
 41. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. *FEBS J* 2011;278(10):1598-609. doi:10.1111/j.1742-4658.2011.08089.x
 42. Natarajan SR, Krishnamoorthy R, Alshuniaber MA, Al-Anazi KM, Farah MA, Rajagopal P, et al. Identification of FOXM1 as a novel protein biomarker and therapeutic target for colorectal cancer progression: evidence from immune infiltration and bioinformatic analyses. *Int J Biol Macromol* 2024;282(Pt 4):137201. doi:10.1016/j.ijbiomac.2024.137201
 43. Suzuki H, Maruyama R, Yamamoto E, Kai M. Epigenetic alteration and microRNA dysregulation in cancer. *Front Genet* 2013;4:258. doi:10.3389/fgene.2013.00258
 44. Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. *Nat Rev Cancer* 2019;19(3):151-61. doi:10.1038/s41568-019-0109-9
 45. Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. *Science* 2017;355(6330):1147-52. doi:10.1126/science.aam7304
 46. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. *PLoS Genet* 2011;7(2):e1001286. doi:10.1371/journal.pgen.1001286
 47. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. *Cancer Res* 2001;61(8):3225-9.
 48. Rodríguez J, Muñoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. *Proc Natl Acad Sci U S A* 2008;105(50):19809-14. doi:10.1073/pnas.0810133105
 49. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. *Nat Rev Drug Discov* 2006;5(1):37-50. doi:10.1038/nrd1930
 50. Feinberg AP. Epigenetic stochasticity, nuclear structure and cancer: the implications for medicine. *J Intern Med* 2014;276(1):5-11. doi:10.1111/joim.12224
 51. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several CDKs, numerous cyclins and diverse compensatory mechanisms. *Oncogene* 2009;28(33):2925-39. doi:10.1038/onc.2009.170
 52. Nurse P. Ordering S phase and M phase in the cell cycle. *Cell* 1994;79(4):547-50. doi:10.1016/0092-8674(94)90539-8
 53. Malumbres M. Cyclin-dependent kinases. *Genome Biol*

- 2014;15(6):122. doi:[10.1186/gb4184](https://doi.org/10.1186/gb4184)
54. Lim S, Kaldis P. CDKs, cyclins and CKIs: roles beyond cell cycle regulation. *Development* 2013;140(15):3079-93. doi:[10.1242/dev.091744](https://doi.org/10.1242/dev.091744)
 55. Fisher RP. CDKs and cyclins in transition(s). *Curr Opin Genet Dev* 1997;7(1):32-8. doi:[10.1016/s0959-437x\(97\)80106-2](https://doi.org/10.1016/s0959-437x(97)80106-2)
 56. Zeman MK, Cimprich KA. Causes and consequences of replication stress. *Nat Cell Biol* 2014;16(1):2-9. doi:[10.1038/ncb2897](https://doi.org/10.1038/ncb2897)
 57. Sherr CJ. G1 phase progression: cycling on cue. *Cell* 1994;79(4):551-5. doi:[10.1016/0092-8674\(94\)90540-1](https://doi.org/10.1016/0092-8674(94)90540-1)
 58. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. *Curr Opin Cell Biol* 2007;19(2):238-45. doi:[10.1016/j.ceb.2007.02.009](https://doi.org/10.1016/j.ceb.2007.02.009)
 59. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 1997;88(3):323-31. doi:[10.1016/s0092-8674\(00\)81871-1](https://doi.org/10.1016/s0092-8674(00)81871-1)
 60. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. *Proc Natl Acad Sci U S A* 1990;87(19):7555-9. doi:[10.1073/pnas.87.19.7555](https://doi.org/10.1073/pnas.87.19.7555)
 61. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. *Clin Cancer Res* 2010;16(4):1094-9. doi:[10.1158/1078-0432.Ccr-09-0787](https://doi.org/10.1158/1078-0432.Ccr-09-0787)
 62. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144(5):646-74. doi:[10.1016/j.cell.2011.02.013](https://doi.org/10.1016/j.cell.2011.02.013)
 63. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature* 1997;386(6625):623-7. doi:[10.1038/386623a0](https://doi.org/10.1038/386623a0)
 64. O'Connor MJ. Targeting the DNA damage response in cancer. *Mol Cell* 2015;60(4):547-60. doi:[10.1016/j.molcel.2015.10.040](https://doi.org/10.1016/j.molcel.2015.10.040)
 65. Liang Y, Lin SY, Brunicaudi FC, Goss J, Li K. DNA damage response pathways in tumor suppression and cancer treatment. *World J Surg* 2009;33(4):661-6. doi:[10.1007/s00268-008-9840-1](https://doi.org/10.1007/s00268-008-9840-1)
 66. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. *Nat Rev Genet* 2009;10(5):295-304. doi:[10.1038/nrg2540](https://doi.org/10.1038/nrg2540)
 67. Feinberg AP, Tycko B. The history of cancer epigenetics. *Nat Rev Cancer* 2004;4(2):143-53. doi:[10.1038/nrc1279](https://doi.org/10.1038/nrc1279)
 68. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet* 2007;8(4):286-98. doi:[10.1038/nrg2005](https://doi.org/10.1038/nrg2005)
 69. Shen H, Laird PW. Interplay between the cancer genome and epigenome. *Cell* 2013;153(1):38-55. doi:[10.1016/j.cell.2013.03.008](https://doi.org/10.1016/j.cell.2013.03.008)
 70. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet* 2006;38(7):787-93. doi:[10.1038/ng1834](https://doi.org/10.1038/ng1834)
 71. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. *J Mol Diagn* 2008;10(1):13-27. doi:[10.2353/jmoldx.2008.070082](https://doi.org/10.2353/jmoldx.2008.070082)
 72. Kouzarides T. Chromatin modifications and their function. *Cell* 2007;128(4):693-705. doi:[10.1016/j.cell.2007.02.005](https://doi.org/10.1016/j.cell.2007.02.005)
 73. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. *Am J Transl Res* 2011;3(2):166-79.
 74. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. *J Clin Invest* 2014;124(1):30-9. doi:[10.1172/jci69738](https://doi.org/10.1172/jci69738)
 75. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nat Rev Genet* 2012;13(5):343-57. doi:[10.1038/nrg3173](https://doi.org/10.1038/nrg3173)
 76. Audia JE, Campbell RM. Histone modifications and cancer. *Cold Spring Harb Perspect Biol* 2016;8(4):a019521. doi:[10.1101/cshperspect.a019521](https://doi.org/10.1101/cshperspect.a019521)
 77. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006;6(11):857-66. doi:[10.1038/nrc1997](https://doi.org/10.1038/nrc1997)
 78. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. *Curr Opin Oncol* 2010;22(1):35-45. doi:[10.1097/CCO.0b013e328333dcb](https://doi.org/10.1097/CCO.0b013e328333dcb)
 79. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. *Cancer Cell* 2016;29(4):452-63. doi:[10.1016/j.ccell.2016.03.010](https://doi.org/10.1016/j.ccell.2016.03.010)
 80. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. *Cell* 2018;172(3):393-407. doi:[10.1016/j.cell.2018.01.011](https://doi.org/10.1016/j.cell.2018.01.011)
 81. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res* 2011;21(3):381-95. doi:[10.1038/cr.2011.22](https://doi.org/10.1038/cr.2011.22)
 82. Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. *Nat Rev Genet* 2016;17(5):284-99. doi:[10.1038/nrg.2016.13](https://doi.org/10.1038/nrg.2016.13)
 83. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. *Nat Rev Cancer* 2013;13(7):497-510. doi:[10.1038/nrc3486](https://doi.org/10.1038/nrc3486)
 84. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet* 2012;13(7):484-92. doi:[10.1038/nrg3230](https://doi.org/10.1038/nrg3230)
 85. Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. *Nat Rev Genet* 2019;20(2):109-27. doi:[10.1038/s41576-018-0074-2](https://doi.org/10.1038/s41576-018-0074-2)
 86. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. *Cancer Res* 2005;65(10):3980-5. doi:[10.1158/0008-5472.Can-04-3995](https://doi.org/10.1158/0008-5472.Can-04-3995)
 87. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. *Oncogene* 2002;21(35):5427-40. doi:[10.1038/sj.onc.1205600](https://doi.org/10.1038/sj.onc.1205600)
 88. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. *Nat Rev Cancer* 2009;9(6):400-14. doi:[10.1038/nrc2657](https://doi.org/10.1038/nrc2657)
 89. Chu IM, Hengst L, Slingerland JM. The CDK inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. *Nat Rev Cancer* 2008;8(4):253-67. doi:[10.1038/nrc2347](https://doi.org/10.1038/nrc2347)
 90. Natarajan SR, Krishnamoorthy R, Alshuniaber MA, Gatasheh MK, Rajagopal P, Veeraraghavan VP, et al. KDM1A facilitates oncogenic potential in colorectal cancer progression through the activation of AXIN/GSK3 β -catenin signaling pathways: evidence from integrated transcriptomics and in vitro studies. *J Gene Med* 2025;27(11):e70053. doi:[10.1002/jgm.70053](https://doi.org/10.1002/jgm.70053)
 91. Issa JP, Kantarjian HM. Targeting DNA methylation. *Clin Cancer Res* 2009;15(12):3938-46. doi:[10.1158/1078-0432.Ccr-08-2783](https://doi.org/10.1158/1078-0432.Ccr-08-2783)
 92. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. *Nat Rev Genet* 2016;17(10):630-41. doi:[10.1038/nrg.2016.93](https://doi.org/10.1038/nrg.2016.93)
 93. Momparler RL, Bovenzi V. DNA methylation and cancer. *J Cell Physiol* 2000;183(2):145-54. doi:[10.1002/\(sici\)1097-4652\(200005\)183:2<145::Aid-jcp1>3.0.Co;2-v](https://doi.org/10.1002/(sici)1097-4652(200005)183:2<145::Aid-jcp1>3.0.Co;2-v)
 94. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. *Nat Biotechnol* 2010;28(10):1069-78. doi:[10.1038/nbt.1678](https://doi.org/10.1038/nbt.1678)
 95. Jackson K, Devaraj E, Lakshmi T, Rajeshkumar S, Dua K, Chellappan DK, et al. Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells. *Bioinformation* 2020;16(11):817-27. doi:[10.6026/97320630016817](https://doi.org/10.6026/97320630016817)
 96. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 2006;5(9):769-84. doi:[10.1038/nrd2133](https://doi.org/10.1038/nrd2133)
 97. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. *J Cell Biochem* 2009;107(4):600-8.

- doi:[10.1002/jcb.22185](https://doi.org/10.1002/jcb.22185)
98. Venkatesalu S, Dilliyappan S, Satish Kumar A, Palaniyandi T, Baskar G, Ravi M, et al. Prospectives and retrospectives of microfluidics devices and lab-on-a-chip emphasis on cancer. *Clin Chim Acta* 2024;552:117646. doi:[10.1016/j.cca.2023.117646](https://doi.org/10.1016/j.cca.2023.117646)
 99. Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. *Trends Cancer* 2017;3(1):39-55. doi:[10.1016/j.trecan.2016.11.006](https://doi.org/10.1016/j.trecan.2016.11.006)
 100. Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. *Nat Rev Clin Oncol* 2020;17(2):75-90. doi:[10.1038/s41571-019-0266-5](https://doi.org/10.1038/s41571-019-0266-5)
 101. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell* 2015;162(5):974-86. doi:[10.1016/j.cell.2015.07.011](https://doi.org/10.1016/j.cell.2015.07.011)
 102. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. *Science* 2017;357(6348):eaal2380. doi:[10.1126/science.aal2380](https://doi.org/10.1126/science.aal2380)
 103. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. *Nature* 2013;502(7472):480-8. doi:[10.1038/nature12751](https://doi.org/10.1038/nature12751)
 104. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. *Nat Rev Drug Discov* 2012;11(5):384-400. doi:[10.1038/nrd3674](https://doi.org/10.1038/nrd3674)
 105. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010;141(1):69-80. doi:[10.1016/j.cell.2010.02.027](https://doi.org/10.1016/j.cell.2010.02.027)
 106. Clark SJ, Lee HJ, Smallwood SA, Kelsey G, Reik W. Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. *Genome Biol* 2016;17:72. doi:[10.1186/s13059-016-0944-x](https://doi.org/10.1186/s13059-016-0944-x)
 107. Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. *Nat Methods* 2016;13(2):127-37. doi:[10.1038/nmeth.3733](https://doi.org/10.1038/nmeth.3733)
 108. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. *Hum Mol Genet* 2007;16 Spec No 1:R50-9. doi:[10.1093/hmg/ddm018](https://doi.org/10.1093/hmg/ddm018)
 109. Huarte M. The emerging role of lncRNAs in cancer. *Nat Med* 2015;21(11):1253-61. doi:[10.1038/nm.3981](https://doi.org/10.1038/nm.3981)
 110. Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. *Trends Cancer* 2017;3(5):372-86. doi:[10.1016/j.trecan.2017.04.004](https://doi.org/10.1016/j.trecan.2017.04.004)